Introducing NMDP, formerly known as the National Marrow Donor Program and Be The Match. Our name has changed but our mission has not: We save lives through cell therapy. Learn More

Two drugs, isatuximab and lenalidomide, to treat multiple myeloma that doctors consider high-risk after autologous (your own cells) blood or marrow transplant (BMT)


18 - 70

Phase 2

1 Location


Clinical Trial Goal

To find out if the combination of isatuximab and lenalidomide is safe and works well to treat multiple myeloma that doctors consider high-risk after autologous BMT

You may be able to join this trial if you:

  • Are 18 - 70 years old
  • Have multiple myeloma that doctors consider high-risk
  • Have had or plan to have an autologous BMT
  • Agree to have other standard tests done to see if you can be in the clinical trial 

Trial Details

Isatuximab is a monoclonal antibody that targets CD38 on certain cells.
Lenalidomide is a drug that blocks growth of cancer cells.
You’ll get the following 2 - 6 months after autologous BMT: 
  • Isatuximab – Given as an intravenous (IV) infusion
  • Lenalidomide - A pill that you take by mouth

You may continue treatment for up to 3 years. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 6 years.

The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. 


Muzzaffar Qazilbash, MD, (713) 745-3458,


M D Anderson Cancer CenterRecruiting

Houston, Texas
Muzaffar Qazilbash, MD, 713-745-3458, record

NCT05776979. First posted on 3/20/23

Call center employee on the phone offering help to a caller

Questions? Contact our Clinical Trials Navigator